Tesamorelin: FDA Record, Trials & Compounded Cost

Last verified: 23 August 2026. Disclosure: some links on this page are affiliate links; if you sign up with a provider through one, we may earn a commission. That does not change what we report. See our affiliate disclosure and how we review.

Tesamorelin is unusual in the peptide world for one reason: there is a real, FDA-approved prescription drug behind it. Most peptides sold through telehealth exist only as compounded products with no approved reference drug. Tesamorelin has a 15-year regulatory paper trail, published phase 3 trials, and a labeled indication. That makes it one of the few peptides where you can check the claims against primary documents, so this page does exactly that.

The FDA record

FDA approved Egrifta (tesamorelin for injection), made by Theratechnologies, on 12 November 2010, as the first treatment to reduce excess abdominal fat in adults with HIV and lipodystrophy. The product line has been updated twice since: Egrifta SV, a higher-concentration version of the original, and Egrifta WR, a new "F8" formulation approved 25 March 2025 that is reconstituted weekly instead of daily and uses less than half the injection volume. The approved dose of the original formulation is 2 mg injected subcutaneously once daily.

Note what the approval covers: HIV-associated lipodystrophy, and nothing else. Every other use you see marketed — general belly-fat reduction, longevity, body composition in healthy adults — is off-label.

What the trials actually showed

The approval rested on two 26-week phase 3 studies in people with HIV-associated lipodystrophy. In the first, visceral adipose tissue (VAT, the fat around the organs) fell 18% on tesamorelin while rising 2% on placebo. In the second, VAT fell 14% versus a 2% decline on placebo. Waist-circumference reductions were sustained through 52 weeks in extension data. Two caveats matter for anyone reading those numbers as a preview of their own results: the trials were run in a specific patient population, not healthy adults, and in the trial extensions the fat returned after treatment stopped — tesamorelin manages visceral fat while you take it; it does not cure anything.

Side effects in the labeled trials

The most common adverse events versus placebo were injection-site redness (8.5% vs 2.7%) and itching (7.6% vs 0%), joint pain (13% vs 11%), muscle pain (5.5% vs 1.9%), and peripheral swelling (6.1% vs 2.3%). Because tesamorelin raises growth hormone and IGF-1, the label flags glucose intolerance and recommends stopping in patients whose IGF-1 rises sharply without clear benefit. It is not for use in active malignancy or pregnancy. A prescriber should be screening for all of this — which is one concrete question to ask any telehealth service before you pay.

The compounded-version question

What telehealth platforms sell is not Egrifta. It is compounded tesamorelin prepared by pharmacy partners. Because an FDA-approved version exists, compounding pharmacies operate under restrictions on producing what regulators call "essentially a copy" of a commercially available drug, and the details of how each provider's product is formulated and justified are rarely published. Tesamorelin sits in a different regulatory category from peptides like BPC-157, which have no approved drug behind them at all — our Peptide Legal Status Tracker maps where each substance stands, with links to the underlying FDA documents.

What it costs through telehealth

Brand Egrifta is a specialty drug typically billed through insurance at specialty-drug prices. Compounded telehealth versions are listed at a small fraction of that. As of 23 August 2026, Live Vital lists tesamorelin at $166/month with prescriber review and pharmacy fulfillment included — the lowest listed price for tesamorelin among the providers we track in our peptide clinic comparison. (We reviewed Live Vital's full catalog and what we could and couldn't verify here.)

Check tesamorelin pricing at Live Vital →

Bottom line

Tesamorelin is the rare peptide with real evidence: an approved drug, two placebo-controlled phase 3 trials, and a defined safety profile. It is also a drug whose approved use is narrow, whose benefits reverse on discontinuation, and whose telehealth versions are compounded products rather than the approved brand. If you're considering it, the questions that matter are whether a licensed prescriber will actually evaluate you, which pharmacy compounds it, and how IGF-1 and glucose will be monitored. Get those answered in writing.

This article reports published information for consumer research and is not medical advice. Sources: FDA approval records and press coverage of the 12 Nov 2010 Egrifta approval and 25 Mar 2025 Egrifta WR approval; phase 3 results as reported at approval. Prices as listed by providers on the date above.